StockMacro
Menu

Jennifer Kayden Lee

Insider (Form 4 reporting owner): EVP, Head of North America CIK 1801372Name as filed: Lee Jennifer KaydenIts filings on EDGARAll insiders

Measures activity, not value. Not investment advice.

Since 15 Feb 2022, sold $16.9M in 19 sales (11 under a 10b5-1 plan set in advance) of Rhythm Pharmaceuticals.

Companies

Role on the latest Form 4 for each; open-market trades counted
CompanyRoleTrades fromtoPurchasesSales
Rhythm Pharmaceuticals RYTMEVP, Head of North America15 Feb 202213 Aug 2026–19$16.9M

What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.

Median return minus the sector fund, in percentage points; "too few trades" under 5
Open-market tradesAfter 3 monthsAfter 6 monthsAfter 12 months
After sales-1.7 pts10 trades, 50% above the sector+31.1 pts9 trades, 78% above the sector+65.9 pts9 trades, 100% above the sector

For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.

By year

Counted open-market trades, by trade date
YearPurchasesBoughtSalesSoldNet
2026––1$8.9M-$8.9M
2025––5$866K-$866K
2024––5$5.9M-$5.9M
2023––7$1.2M-$1.2M
2022––1$4K-$4K

Every trade

20, newest first; open-market purchases and sales only
Trade dateCompanySideSharesPriceValuePlanned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. Filing
13 Aug 2026Rhythm Pharmaceuticals RYTMSellafter exercising options75,834$117.38$8.9M10b5-1 planForm 4filed 14 Aug 2026
19 Feb 2025Rhythm Pharmaceuticals RYTMSellafter exercising options2,035$57.22$116K10b5-1 planForm 4filed 19 Feb 2025
12 Feb 2025Rhythm Pharmaceuticals RYTMSell3,020$57.03$172K10b5-1 planForm 4filed 14 Feb 2025
10 Feb 2025Rhythm Pharmaceuticals RYTMSellafter exercising options5,216$58.63$306K10b5-1 planForm 4filed 11 Feb 2025
5 Feb 2025Rhythm Pharmaceuticals RYTMSell3,066$60.55$186K10b5-1 planForm 4filed 7 Feb 2025
4 Feb 2025Rhythm Pharmaceuticals RYTMSellafter exercising options1,447$59.43$86KNoForm 4filed 4 Feb 2025
11 Nov 2024Rhythm Pharmaceuticals RYTMSellafter exercising options66,861$66.33$4.4M10b5-1 planForm 4filed 13 Nov 2024
20 Mar 2024Rhythm Pharmaceuticals RYTMSell18,235$38.77$707KNoForm 4filed 22 Mar 2024
19 Mar 2024Rhythm Pharmaceuticals RYTMSell15,515$39.22$608KNoForm 4filed 19 Mar 2024
12 Feb 2024Rhythm Pharmaceuticals RYTMSellafter exercising options1,638$50.80$83KNoForm 4filed 13 Feb 2024
1 Feb 2024Rhythm Pharmaceuticals RYTMSellafter exercising options1,492$45.06$67KNoForm 4filed 5 Feb 2024
14 Nov 2023Rhythm Pharmaceuticals RYTMSellafter exercising options13,677$32.01$438K10b5-1 planForm 4filed 16 Nov 2023
8 Nov 2023Rhythm Pharmaceuticals RYTMSellafter exercising options9,150$28.44$260K10b5-1 planForm 4filed 13 Nov 2023
3 Nov 2023Rhythm Pharmaceuticals RYTMSellafter exercising options80$28.00$2K10b5-1 planForm 4filed 7 Nov 2023
5 Sep 2023Rhythm Pharmaceuticals RYTMSellafter exercising options6,166$28.05$173K10b5-1 planForm 4filed 7 Sep 2023
7 Aug 2023Rhythm Pharmaceuticals RYTMSellafter exercising options12,941$24.24$314K10b5-1 planForm 4filed 9 Aug 2023
14 Feb 2023Rhythm Pharmaceuticals RYTMSellafter exercising options635$26.87$17KNot statedForm 4filed 14 Feb 2023
9 Feb 2023Rhythm Pharmaceuticals RYTMSellamended filing (4/A), not counted again1,204$27.51$33KNot statedForm 4/Afiled 14 Feb 2023
9 Feb 2023Rhythm Pharmaceuticals RYTMSellafter exercising options1,192$27.66$33KNot statedForm 4filed 13 Feb 2023
15 Feb 2022Rhythm Pharmaceuticals RYTMSellafter exercising options722$6.10$4KNot statedForm 4filed 15 Feb 2022

From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.